Document:

Exhibit 10.1

Dear :

On behalf of 180 Life Sciences Corp., a Delaware corporation (the
“Company”), I am pleased to extend to you an offer to join the Company’s Board of Directors (the “Board”),
effective June 15, 2021. This offer is contingent upon (i) your completion of the enclosed Officers, Directors, Managers and Principal
Stockholders Questionnaire, (ii) receipt of a background check satisfactory to the Company, (iii) your confirmation of the enclosed
Policy on Insider Trading and Policy on Control and Disclosure of Confidential Information, and (iv) formal approval of your appointment
by the Board. 

The Company’s current schedule includes approximately four
regular meetings of the Board, which are currently held by telephone/video conference, but may in the future be held in person in a convenient
location plus additional special meetings as called by the Board from time to time which usually take place by telephone/video conference.
In addition to your attendance at Board meetings, we expect to take advantage of your expertise by reaching out to you for advice and
counsel between meetings. To the extent that you are appointed as a member of the Audit Committee, you will need to meet at least quarterly
with the other members of the committee around the time of quarterly and annual earnings releases and related filings with the SEC.

As a member of the Board, you will owe fiduciary duties to the Company
and its stockholders, such as the duty of care, duty of loyalty and the duty of disclosure, which include protecting Company proprietary
information from unauthorized use or disclosure.

The following summarizes the compensation that will be provided to
you effective upon your appointment to the Board: 

 

	 	•	 	Option Grant: You will receive an initial option grant to purchase $425,000 of value of shares of the Company’s common stock (value per share and number of shares determined by the Black-Scholes calculation on the date of grant) (the “Initial Option Grant”). To the extent this grant results in less than an option to purchase 100,000 shares of the Company’s common stock, it is expected that the difference in shares between the Initial Option Grant and 100,000 shares would be granted (Second Year Option Grant) in the next compensation year. Compensation year means the period from one annual meeting of shareholders to the next following annual meeting of shareholders. The Initial Option Grant will vest as to 1/48 of the balance of the option shares upon each month of service after the date of grant and have an exercise price per share equal to the closing sales price of a share of common stock on the grant date. The Second Year Option Grant, to the extent later granted by the Board, will vest as to 1/36 of the balance of the option shares upon each month of service after the date of grant and have an exercise price per share equal to the closing sales price of a share of common stock on the grant date. Although it is anticipated that no additional option grants will be made for three (3) years after the Second Year Option Grant, you also will be eligible to receive future option (or other equity) grants for continued Board service pursuant to the Company’s then current outside director compensation policy. 

 

    1

     

    

 

	 	•	 	Cash Fees: Initially, your cash compensation will consist of $40,000 per compensation year for an annual retainer fee plus additional committee fees. Committee chair fees range from $10,000 to $15,000 per year and committee member fees range from $5,000 to $7,500 per year. Depending on whether you are a committee chair and which committees you sit on, total cash fees (retainer plus committee fees) will range from approximately $55,000 on the lower end to approximately $65,000 on the higher end. After you become a Board member, we will discuss committee chairing and membership; however, it is contemplated that you will serve on one or more of the Compensation Committee, Audit Committee, Risk, Safety and Regulatory Committee, and/or Nominating and Corporate Governance Committee. In addition, the Board may add other committee in the future. All such appointments are subject to the Board’s discretion. Cash fee payments will be made one calendar quarter in arrears and will be pro-rated for partial quarters. The Company does not pay incremental fees for attendance of Board meetings or for telephone/video conferences but will reimburse you for reasonable travel expenses for attending in-person Board meetings and other Board related expenses, subject to compliance with the Company’s reimbursement policies. 

The compensation set forth above is subject to change from time to
time in the future as determined by the Board. In addition, the Company’s option plan outlines change in control provisions,
termination rights, and other matters related to the option grants.

Enclosed are the following documents for your completion: 

		·	Officers, Directors, Managers and Principal Stockholders Questionnaire 

		·	Policy on Insider Trading and Policy on Control and Disclosure of Confidential
Information 

This offer is submitted to you with the understanding that you will
tender your resignation as a member of the Board in the event that you are not in compliance with the Company’s then applicable
policies, codes or charters (including those set forth above). Should you accept this offer, you are representing to us that you (i) do
not know of any conflict which would restrict your ability to serve on the Board and (ii) will not provide the Company with any documents,
records, or other confidential information in violation of the rights of other parties.

Consistent with the Company’s governing documents, while the
Board has authority to appoint you as a member of the Board, your continued service on the Board will be subject to stockholder approval
at the next annual meeting of stockholders. Nothing in this offer should be construed to interfere with or otherwise restrict in any way
the rights of the Company and the Company’s stockholders to remove any individual from the Board at any time in accordance with
the provisions of applicable law.

You will also be entitled to indemnification for your services as
a Board member in accordance with the Company’s standard form of indemnification agreement and the governing documents of the Company.

You are free to end your relationship as a member of the Board at
any time and for any reason. In addition, your right to serve as a member of the Board is subject to the provisions of the Company’s
charter documents.

    2

     

    

 

The terms in this letter agreement supersede any other agreements
or promises made to you by anyone, whether oral or written, and comprise the final, complete and exclusive agreement between you and the
Company regarding your service on the Board. Nothing in this letter should be construed as an offer of employment.

While you serve on the Board, you will be expected to notify the
Company’s legal counsel of any conflicts of interests that may arise with respect to the Company.

I hope that you will accept our offer to join the Company’s
Board of Directors and I look forward to a productive future relationship. If you agree with the above, please indicate your agreement
with these terms and accept this offer by signing and dating this letter below.

Sincerely,

 

James M. Woody, M.D., Ph.D.

 

 

Acknowledged and Agreed:

 

 

Board member name

 

Date:_________________

 

    3Exhibit 10.2

 

SECOND AMENDMENT TO 

EMPLOYMENT AGREEMENT

 

This Second Amendment to Employment
Agreement (this “Amendment”), dated May __, 2021, and effective for all purposes as of November 6, 2020 (the
“Effective Date”), amends that certain Employment Agreement dated February 24, 2021, as amended by the First
Amendment and Correction to Employment Agreement dated March 1, 2021 (“the “First Amendment” and such
Employment Agreement as amended by the First Amendment, the “Employment Agreement”), by and between Ozan Pamir,
an individual (“Pamir”) and Katexco Pharmaceuticals Corp., a British Columbia corporation (“Katexco”),
and 180 Life Sciences Corp., a Delaware corporation, and the indirect parent company of Katexco (“180 Life”),
on, and subject to, the terms below. Certain capitalized terms used below but not otherwise defined shall have the meanings given to such
terms in the Employment Agreement.

 

WHEREAS,
the First Amendment provided for Pamir to receive payment from the Company’s subsidiary, Katexco Pharmaceuticals Corp., a British
Columbia corporation, instead of 180 Life; and

 

WHEREAS,
Executive, Katexco and 180 Life desire to enter into this Amendment to amend the Employment Agreement on the terms and subject to the
conditions set forth below.

 

NOW,
THEREFORE, in consideration of the premises and the mutual covenants, agreements, and considerations herein contained, and other good
and valuable consideration, which consideration the parties hereby acknowledge and confirm the receipt and sufficiency thereof, the parties
hereto agree as follows:

 

1.              
Amendments to Employment Agreement. Effective as of the Effective Date:

 

(a)            
“Section 3(g) of the Employment Agreement is amended and restated as follows:

 

“(g)All cash compensation payable
to Executive pursuant to this Agreement shall be paid to Executive by the Company.”

 

2.              
Effect of Amendment. Upon the effectiveness of this Amendment, each reference in the Employment
Agreement to “Employment Agreement”, “Agreement,”
“hereunder,” “hereof,”
“herein” or words of like import shall mean and be a reference to such Employment
Agreement, as applicable, as modified and amended hereby.

 

3.              
Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the State of Delaware,
without reference to conflicts of law principles.

 

4.              
Heirs, Successors and Assigns. This Amendment shall bind and inure to the benefit of the parties and their respective
successors and permitted assigns. Neither party shall be able to assign this Amendment without the prior written consent of the other
party.

 

 

    Page 1 of 3
Second Amendment to Employment Agreement

     

    

 

5.              
Counterparts and Signatures. This Amendment and any signed agreement or instrument entered into in connection with this
Amendment, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the
same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar
attachment to electronic mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and
respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original
signed version thereof delivered in person. No party shall raise the use of Electronic Delivery to deliver a signature or the fact that
any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation
of a contract, and each such party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

 

 

 

[Remainder of page left intentionally
blank. Signature page follows.]

 

 

 

 

 

    Page 2 of 3
Second Amendment to Employment Agreement

     

    

 

 

IN WITNESS
WHEREOF, the parties hereto have executed this Amendment as of the day and year first above written to be effective as of the Effective
Date.

 

	EXECUTIVE	 	 
	 	 	 	 
	 	 	 	 
	 	 /s/ Ozan Pamir	 
	 	Ozan Pamir	 
	 	 	 	 
	 	 	 	 
	KATEXCO	 	 
	 	 	 
	 	Katexco
    Pharmaceuticals Corp.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Ozan Pamir	 
	 	 	 	 
	 	Its:	Chief Financial Officer 	 
	 	 	 	 
	 	Printed Name:	Ozan Pamir	 
	 	 	 	 
	180 LIFE	 	 
	 	 	 	 
	 	180 Life Sciences Corp.	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ James N. Woody, M.D., Ph.D. 	 
	 	 	 	 
	 	Its:	Chief Executive Officer 	 
	 	 	 	 
	 	Printed Name:	James N. Woody, M.D., Ph.D. 	 

 

    Page 3 of 3
Second Amendment to Employment Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]